Table 3.
Comparison of CD-based surgery and other NVG surgery outcomes for pre- and postcollapse-stage ONFH
| First author/year | Surgical procedure | Mean age at surgery (years) | Mean follow-up (years) | Number of precollapse ONFH (hips) | Hip survivorship/endpoint | Number of postcollapse ONFH (hips) | Hip survivorship/endpoint |
|---|---|---|---|---|---|---|---|
| Seyler [18]/2008 | Light bulb/NVG/rhBMP-7 (3.5 mg) | 35 | 3 | 22 |
81.8% (18/22) Collapse |
17 |
70.5% (12/17) THA |
| Wang [19]/2010 | Light bulb/DBM, rhBMP | 32.3 | 2.1 | 67 |
92.5% (62/67) THA |
71 |
88.7% (63/71) THA |
| Wang [19]/2010 | CD/BMMNC | 37.5 | 2.3 | 50 |
78% (39/50) Radiological progression |
9 |
66.6% (6/9) Radiological progression |
| Zhang [20]/2013 | Light bulb/BG | 31.3 | Minimum 2 | 71 |
85.4% Collapse |
14 | NA |
| Lim [21]/2013 | Multiple CD/Stem cell | 36.3 | 5 | 79 |
62.7% (64/102) Surgery or HHS < 75 |
49 |
42.1% (24/57) Surgery or HHS < 75 |
| Lim [21]/2013 | Multiple CD | 34.4 | 5 | 23 | 8 | ||
| Feng [22]/2019 | CD/iliac BG/VGTF | 33.2 | 9.7 | None | NA | 84 |
92.8% (78/84) THA |
| Feng [22]/2019 | CD/iliac BG | 32.8 | 9.8 | None | NA | 51 |
78.4% (40/51) THA |
| Tomaru [23]/2019 | CD/BMMNC | 42.2 | 12 | 43 |
51.1% (22/43) Collapse |
37 |
43.2% (16/37) THA |
| Liu [24]/2020 | CD/β-TCP | 36 | 5 | 25 |
45.8% (11/24) THA |
22 |
13.0% (3/23) THA |
| Present study/2020 | CD/BG/HA, β-TCP | 40.1 | 3 | 1 |
100% (1/1) Collapse |
19 |
63.1% (12/19) THA |
Hip survivorship was joint preservation rate with the bottom row as an endpoint
NVG, nonvascularized graft; DBM, demineralized bone matrix; rh, recombinant human; BMP, bone morphogenetic protein; CD, core decompression; BMMNC, bone marrow mononuclear cell; BG, bone graft; VGTF, vascularized greater trochanter flap; β-TCP, beta-tricalcium phosphate; HA, hydroxyapatite; THA, total hip arthroplasty; NA, not applicable; HHS, Harris hip score